CN116349204A - 治疗纤维化的方法 - Google Patents

治疗纤维化的方法 Download PDF

Info

Publication number
CN116349204A
CN116349204A CN202180069900.XA CN202180069900A CN116349204A CN 116349204 A CN116349204 A CN 116349204A CN 202180069900 A CN202180069900 A CN 202180069900A CN 116349204 A CN116349204 A CN 116349204A
Authority
CN
China
Prior art keywords
fibrosis
hydrogen
pulmonary
gli1
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180069900.XA
Other languages
English (en)
Chinese (zh)
Inventor
米格尔·德·洛斯·里奥斯
约翰·胡德
安妮塔·迪弗朗西斯科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endeavour Biopharmaceutical Co
Original Assignee
Endeavour Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endeavour Biopharmaceutical Co filed Critical Endeavour Biopharmaceutical Co
Publication of CN116349204A publication Critical patent/CN116349204A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180069900.XA 2020-10-13 2021-10-13 治疗纤维化的方法 Pending CN116349204A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (1)

Publication Number Publication Date
CN116349204A true CN116349204A (zh) 2023-06-27

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180069900.XA Pending CN116349204A (zh) 2020-10-13 2021-10-13 治疗纤维化的方法

Country Status (8)

Country Link
US (4) US11628167B2 (enExample)
EP (1) EP4229828A4 (enExample)
JP (1) JP2023546536A (enExample)
KR (1) KR20230107568A (enExample)
CN (1) CN116349204A (enExample)
AU (1) AU2021360767A1 (enExample)
CA (1) CA3198661A1 (enExample)
WO (1) WO2022081661A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
AU2024230449A1 (en) * 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191736A1 (en) * 2013-05-28 2014-12-04 Redx Pharma Limited Heterocyclic compounds as hedgehog signaling pathway inhibitors
US9000023B2 (en) * 2009-06-19 2015-04-07 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
US20160341726A1 (en) * 2014-02-06 2016-11-24 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
WO2018082587A1 (zh) * 2016-11-04 2018-05-11 上海瑛派药业有限公司 Hedgehog通路抑制剂在治疗纤维化疾病中的应用
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases
WO2020018904A1 (en) * 2018-07-19 2020-01-23 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (enExample) 1977-06-03 1981-03-07 Pfizer
ZA97288B (en) 1996-01-15 1998-07-14 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
JP2018535238A (ja) 2015-11-30 2018-11-29 イグナイタ インコーポレイテッド 局所製剤
CN116349204A (zh) * 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
AU2024230449A1 (en) 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9000023B2 (en) * 2009-06-19 2015-04-07 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
WO2014191736A1 (en) * 2013-05-28 2014-12-04 Redx Pharma Limited Heterocyclic compounds as hedgehog signaling pathway inhibitors
US20160341726A1 (en) * 2014-02-06 2016-11-24 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
WO2018082587A1 (zh) * 2016-11-04 2018-05-11 上海瑛派药业有限公司 Hedgehog通路抑制剂在治疗纤维化疾病中的应用
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases
WO2020018904A1 (en) * 2018-07-19 2020-01-23 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENGLIN WANG ET AL.: "Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 26, no. 12, 1 May 2018 (2018-05-01), pages 3308 - 3320 *
JOHANNA BENDELL ET AL.: "Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma", CLIN CANCER RES., vol. 24, no. 9, 1 May 2018 (2018-05-01), pages 2082 - 2091 *
ZHENMEI GAO ET AL.: "Effect of mutations on drug resistance of smoothened receptor toward inhibitors probed by molecular modeling", CHEMICAL PHYSICS LETTERS, vol. 741, 17 January 2020 (2020-01-17), pages 1 - 8 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Also Published As

Publication number Publication date
US11628167B2 (en) 2023-04-18
CA3198661A1 (en) 2022-04-21
US20240342170A1 (en) 2024-10-17
AU2021360767A9 (en) 2024-02-08
KR20230107568A (ko) 2023-07-17
JP2023546536A (ja) 2023-11-02
US20230201195A1 (en) 2023-06-29
WO2022081661A1 (en) 2022-04-21
EP4229828A4 (en) 2024-08-28
US12295954B2 (en) 2025-05-13
US20220265650A1 (en) 2022-08-25
EP4229828A1 (en) 2023-08-23
AU2021360767A1 (en) 2023-04-27
US20250235452A1 (en) 2025-07-24
US12213974B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US12213974B2 (en) Methods of treating fibrosis
US12605377B2 (en) Methods of treating fibrosis
Belcaid et al. Perioperative pain management in morbid obesity
Gonano et al. Comparison of economical aspects of interscalene brachial plexus blockade and general anaesthesia for arthroscopic shoulder surgery
Howton et al. Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma
Kim et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas
JP6170040B2 (ja) ピルフェニドン及び選択された患者における抗線維化療法
Steinberg et al. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients
CN120916760A (zh) 治疗纤维化的方法
Sinatra et al. Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: the effects on effort-dependent pain and pulmonary function
ES2811124T3 (es) Uso de reslizumab para tratar el asma eosinofílica moderada a grave
Shashi et al. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case–control study
Kerstjens et al. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients
Taniguchi et al. Effect of scheduled intravenous acetaminophen on postoperative nausea and vomiting in patients undergoing laparoscopic gynecologic surgery
TWI750129B (zh) 作為血液學毒性生物標記之ｇｄｆ-１５
US9446029B2 (en) Use of NK-1 receptor antagonists in management of visceral pain
US20200368246A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
McElroy et al. Evaluation of the safety of ketorolac in postsurgical infants less than six months of age
Ziqiang et al. Effect of esketamine on the EC50 of remifentanil for blunting cardiovascular responses to endotracheal intubation in female patients under general anesthesia: a sequential allocation dose-finding study
Mieszczański et al. Successful Anesthetic Management for Obese Patients with Interstitial Lung Disease Undergoing Laparoscopic Sleeve Gastrectomy: A Bridge to Improved Lung Transplant Eligibility
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
Samir et al. Dexmedetomidine versus propofol for sedation in stereotactic brain biopsy: a comparative study
TW202535397A (zh) 給藥方案
Nakashima et al. Afatinib-induced bronchiolitis obliterans
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination